OPDIVO vs TAFINLAR

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. OPDIVO and TAFINLAR are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	OPDIVO	TAFINLAR
Rating	72/100	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	NIVOLUMAB	DABRAFENIB MESYLATE
Manufacturer	Bristol Myers Squibb	Novartis
Dosage forms	Injectable	Capsule, Tablet
Drug class	Programmed Death Receptor-1 Blocking Antibody	—
Boxed warning	None	None
Treats	Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma	Melanoma

opdivo tafinlar

Rating

72/100

70/100

Pharmacy pays

—

Type

Active ingredient

NIVOLUMAB

DABRAFENIB MESYLATE

Manufacturer

Bristol Myers Squibb

Novartis

Dosage forms

Injectable

Capsule, Tablet

Drug class

Programmed Death Receptor-1 Blocking Antibody

—

Boxed warning

None

Treats

Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma

Melanoma

Frequently asked questions

Which is better-rated, Opdivo or Tafinlar?

By our independent rating, Opdivo scores higher — 3.6 vs 3.5 out of 5 for Tafinlar. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Opdivo and Tafinlar?

Opdivo contains Nivolumab, while Tafinlar contains Dabrafenib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.